Table 3.
Cytogenetic alterations in WHOest, WHOnew, and ICCnew
| MP-WHOest n = 551∗ |
MD-WHOest n = 654∗ |
WHOnew n = 356∗ |
q value† MD-WHOest vs WHOnew | ICCnew N = 241∗ |
q value† MD-WHOest vs ICCnew | |
|---|---|---|---|---|---|---|
| Clinical karyotype | <0.001 | <0.001 | ||||
| Normal karyotype | 401/538 (75%) | 515/649 (79%) | 211/351 (60%) | 146/240 (61%) | ||
| Aberrant1 | 105/538 (20%) | 107/649 (16%) | 105/351 (30%) | 74/240 (31%) | ||
| Aberrant2 | 20/538 (3.7%) | 9/649 (1.4%) | 22/351 (6.3%) | 10/240 (4.2%) | ||
| Aberrant3 | 5/538 (0.9%) | 6/649 (0.9%) | 4/351 (1.1%) | 3/240 (1.3%) | ||
| Complex >3 | 7/538 (1.3%) | 12/649 (1.8%) | 9/351 (2.6%) | 7/240 (2.9%) | ||
| Total aberrations | 0.4 ± 1.0; 0.0 (0.0-10.0) | 0.4 ± 1.1; 0.0 (0.0-13.0) | 0.7 ± 1.5; 0.0 (0.0-15.0) | <0.001 | 0.7 ± 1.7; 0.0 (0.0-15.0) | <0.001 |
| del(5q) | 4/551 (0.7%) | 17/654 (2.6%) | 27/356 (7.6%) | 0.003 | 19/241 (7.9%) | 0.003 |
| chr7 loss | 16/551 (2.9%) | 11/654 (1.7%) | 12/356 (3.4%) | 0.3 | 10/241 (4.1%) | 0.15 |
| del(7q) | 4/551 (0.7%) | 6/654 (0.9%) | 6/356 (1.7%) | 0.6 | 2/241 (0.8%) | >0.9 |
| chr8 gain | 36/551 (6.5%) | 27/654 (4.1%) | 26/356 (7.3%) | 0.13 | 18/241 (7.5%) | 0.2 |
| del(11q) | 4/551 (0.7%) | 1/654 (0.2%) | 5/356 (1.4%) | 0.11 | 3/241 (1.2%) | 0.2 |
| del(12p) | 8/551 (1.5%) | 2/654 (0.3%) | 1/356 (0.3%) | >0.9 | 1/241 (0.4%) | >0.9 |
| chr19 gain | 1/551 (0.2%) | 4/654 (0.6%) | 1/356 (0.3%) | 0.9 | 1/241 (0.4%) | >0.9 |
| del(20q) | 9/551 (1.6%) | 9/654 (1.4%) | 15/356 (4.2%) | 0.036 | 14/241 (5.8%) | 0.003 |
| chr21 gain | 13/551 (2.4%) | 1/654 (0.2%) | 2/356 (0.6%) | 0.5 | 2/241 (0.8%) | 0.4 |
| chrY loss | 18/551 (3.3%) | 45/654 (6.9%) | 49/356 (14%) | 0.003 | 31/241 (13%) | 0.034 |
∗
n / N (%).
†
Wilcoxon rank sum test and Pearson χ2 test with false discovery rate correction for multiple testing.